Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HTX-011-19
- Development stage
- Approved
- Lead developer
- Heron Therapeutics
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
HTX-011-19 is a specific subcutaneous formulation variant of HTX-011, a long-acting, extended-release fixed-dose combination of bupivacaine and meloxicam. Developed by Heron Therapeutics using its proprietary Biochronomer® sustained-release polymer technology, HTX-011-19 contains 58.5 mg of bupivacaine and 1.8 mg of meloxicam per 1 mL. It is designed for the management of postoperative pain, utilizing bupivacaine as a local anesthetic (sodium channel blocker) and meloxicam as a nonsteroidal anti-inflammatory drug (COX inhibitor) to provide dual-acting relief. The formulation was evaluated in a Phase I single ascending dose study to assess safety, tolerability, and pharmacokinetics in healthy subjects.
- Brand names
- ZYNRELEF
- Other names
- bupivacaine + meloxicam
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on HTX-011-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HTX-011-19.